Datos de fase III de olatorepatida --agonista dual sesgado de GLP-1/GIP de Hansoh-- presentados en la EASD

Data ReadoutpositiveolatorepatidaPositive

AI Analysis

Summary

Hansoh presented Phase III data for olatorepatida, a dual GLP-1/GIP agonist, showing 19.3% weight loss at week 48 at the EASD annual meeting in Milan.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase III data showed 19.3% weight loss at week 48

Importance:7/10

Sentiment:

0.70

GLP-1GIPdual agonistobesityEASDweight loss

Related Companies

$HNPHY

Read the original article

Published by PR Newswire Pharma on October 2, 2026 12:41 PM

Read Original